Stem Cells And The Origins Of Barrett's Esophagus:Identification Of Novel Biomarkers And Gene Signatures In Barrett's Esophagus
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 125
- 试验地点
- 2
- 主要终点
- Response to therapy
研究概览
简要总结
The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.
详细描述
This Project is designed to identify biologically-based and clinically-useful biomarkers of tissue at risk for neoplastic progression as well as of response to ablation therapy. These results will result in improved risk stratification in BE and better targeting of resources for patients who are candidates for ablative therapy, while simultaneously providing key information regarding the origins of Barrett's esophagus.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Barrett's esophagus with high grade dysplasia or intramucosal (early) adenocarcinoma.
- •BE length ≥ 2 cm and ≤ 8 cm.
- •Able to return every 3 months for one year after ablation
排除标准
- •Patients who are unable to be compliant with follow-up endoscopies
- •patients who cannot tolerate Proton Pump inhibitors
- •pre-existing esophageal strictures
- •pregnant or nursing women
结局指标
主要结局
Response to therapy
时间窗: one year post ablation
evaulation will be made at 3 month intervals for one year post ablation
次要结局
未报告次要终点
研究者
Kenneth K. Wang
Principal Investigator
Mayo Clinic
